Cargando…
Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy
Standard cancer treatments trigger immune responses that may influence tumor control. The nature of these responses varies depending on the tumor and the treatment modality. We previously reported that radiation and androgen-deprivation therapy (ADT) induce tumor-associated autoantibody responses in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125379/ https://www.ncbi.nlm.nih.gov/pubmed/25114831 http://dx.doi.org/10.4161/onci.29243 |
_version_ | 1782329771644944384 |
---|---|
author | Johnson, Lisa DS Nesslinger, Nancy J Blood, Paul A Chima, Navraj Richier, Lindsay R Ludgate, Charles Pai, Howard H Lim, Jan T Nelson, Brad H Vlachaki, Maria T Lum, Julian J |
author_facet | Johnson, Lisa DS Nesslinger, Nancy J Blood, Paul A Chima, Navraj Richier, Lindsay R Ludgate, Charles Pai, Howard H Lim, Jan T Nelson, Brad H Vlachaki, Maria T Lum, Julian J |
author_sort | Johnson, Lisa DS |
collection | PubMed |
description | Standard cancer treatments trigger immune responses that may influence tumor control. The nature of these responses varies depending on the tumor and the treatment modality. We previously reported that radiation and androgen-deprivation therapy (ADT) induce tumor-associated autoantibody responses in prostate cancer patients. This follow-up analysis was conducted to assess the relationship between autoantibody responses and clinical outcome. Patients with non-metastatic prostate cancer received external beam radiation therapy (EBRT) plus neoadjuvant and concurrent androgen deprivation. Treatment-induced autoantibodies were detected in almost a third of patients receiving combinatorial ADT and EBRT. Unexpectedly, patients that developed autoantibody responses to tumor antigens had a significantly lower 5-year biochemical failure-free survival (BFFS) than patients that did not develop an autoantibody response. Thus, tumor-reactive autoantibodies may be associated with increased risk of biochemical failure and immunomodulation to prevent autoantibody development may improve BFFS for select, high-risk prostate cancer patients receiving both ADT and EBRT. |
format | Online Article Text |
id | pubmed-4125379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-41253792014-08-11 Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy Johnson, Lisa DS Nesslinger, Nancy J Blood, Paul A Chima, Navraj Richier, Lindsay R Ludgate, Charles Pai, Howard H Lim, Jan T Nelson, Brad H Vlachaki, Maria T Lum, Julian J Oncoimmunology Brief Report Standard cancer treatments trigger immune responses that may influence tumor control. The nature of these responses varies depending on the tumor and the treatment modality. We previously reported that radiation and androgen-deprivation therapy (ADT) induce tumor-associated autoantibody responses in prostate cancer patients. This follow-up analysis was conducted to assess the relationship between autoantibody responses and clinical outcome. Patients with non-metastatic prostate cancer received external beam radiation therapy (EBRT) plus neoadjuvant and concurrent androgen deprivation. Treatment-induced autoantibodies were detected in almost a third of patients receiving combinatorial ADT and EBRT. Unexpectedly, patients that developed autoantibody responses to tumor antigens had a significantly lower 5-year biochemical failure-free survival (BFFS) than patients that did not develop an autoantibody response. Thus, tumor-reactive autoantibodies may be associated with increased risk of biochemical failure and immunomodulation to prevent autoantibody development may improve BFFS for select, high-risk prostate cancer patients receiving both ADT and EBRT. Landes Bioscience 2014-06-25 /pmc/articles/PMC4125379/ /pubmed/25114831 http://dx.doi.org/10.4161/onci.29243 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Brief Report Johnson, Lisa DS Nesslinger, Nancy J Blood, Paul A Chima, Navraj Richier, Lindsay R Ludgate, Charles Pai, Howard H Lim, Jan T Nelson, Brad H Vlachaki, Maria T Lum, Julian J Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy |
title | Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy |
title_full | Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy |
title_fullStr | Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy |
title_full_unstemmed | Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy |
title_short | Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy |
title_sort | tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125379/ https://www.ncbi.nlm.nih.gov/pubmed/25114831 http://dx.doi.org/10.4161/onci.29243 |
work_keys_str_mv | AT johnsonlisads tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT nesslingernancyj tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT bloodpaula tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT chimanavraj tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT richierlindsayr tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT ludgatecharles tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT paihowardh tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT limjant tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT nelsonbradh tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT vlachakimariat tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy AT lumjulianj tumorassociatedautoantibodiescorrelatewithpooroutcomeinprostatecancerpatientstreatedwithandrogendeprivationandexternalbeamradiationtherapy |